Physician profile
Peter B Hines
NPI 1932244506
$2,704.52
in general payments reported to CMS, 2019-2025
24 companies · $654 in 2025
The $654 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $439 · 2020: $73.95 · 2021: $182 · 2022: $312 · 2023: $564 · 2024: $480 · 2025: $654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,674 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,673.70 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $415.43 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $391.02 | 2019-2025 | Lokelma, Farxiga |
| Vifor Pharma, INC. | $379.52 | 2019-2024 | Veltassa |
| Amgen INC. | $235.68 | 2019-2025 | Tavneos, Krystexxa |
| Aurinia Pharma U.S., INC. | $224.32 | 2021-2025 | Lupkynis |
| Fresenius USA Marketing, INC. | $131.12 | 2019-2023 | Velphoro, Korsuva |
| Novartis Pharmaceuticals Corporation | $127.74 | 2023-2025 | |
| Mallinckrodt Enterprises LLC | $105.83 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $104.10 | 2019-2025 | Jynarque |
| Travere Therapeutics, INC. | $80.85 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $78.41 | 2020-2024 | Terlivaz, Acthar |
| Calliditas Therapeutics US INC. | $66.34 | 2024-2025 | Tarpeyo |
| Akebia Therapeutics INC | $59.78 | 2022-2024 | Vafseo, Auryxia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.82 | 2023-2025 | Jardiance |
| Novo Nordisk INC | $54.41 | 2024-2025 | Ozempic, Rybelsus |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $43.74 | 2025 | Jardiance |
| Opko Pharmaceuticals, LLC | $23.11 | 2019 | |
| Xeris Pharmaceuticals, INC. | $22.66 | 2025 | Keveyis |
| Daiichi Sankyo INC. | $22.52 | 2019 | |
| Ethicon US, LLC | $21.38 | 2019 | |
| Alexion Pharmaceuticals, INC. | $18.16 | 2022 | |
| Glaxosmithkline, LLC. | $15.11 | 2023 | Benlysta |
| Horizon Therapeutics Plc | $13.40 | 2023 | Krystexxa |
| Arbor Pharmaceuticals, INC. | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Hines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.